9. January 2015

FDA Approves Roche's Blood Screening Assay for Simultaneous Detection and Identification of Three Major Viral Targets

Roche announced today that the FDA has approved the cobasĀ® TaqScreen MPX Test, v2.0 for use in the detection and identification of HIV, HCV, and HBV in donations of human whole blood and blood components including source plasma.


Learn about testing for EGFR in non-small cell lung cancer
What's New

28. September 2015

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

New test is the first to be validated for use of either sample type in a single test.


18. June 2015

Roche receives FDA CLIA waiver for flu A/B test for use on its cobas Liat PCR System

First CLIA-waived, real-time PCR tests for flu and Strep A now available for physician offices and pharmacies.


13. August 2015

Roche acquires GeneWEAVE to strengthen offerings in microbiology diagnostics

Roche today announced that it has signed a definitive agreement to acquire GeneWEAVE BioSciences, Inc., a privately held company focused on innovative, clinical microbiology diagnostics solutions based in Los Gatos, CA, USA.


30. July 2015

Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy

The cobasĀ® EGFR Mutation Test v2 is designed for expanded EGFR mutation detection in non-small cell lung cancer patients.


 Diagnostic and Blood Screening Tests


Roche Molecular Diagnostics (RMD) offers a uniquely broad range of diagnostic and blood screening assays based on the company's Nobel prize-winning PCR technologies.


RMD's tests and automated platforms are focused in the areas of virology, blood screening, HPV, genomics and oncology, microbiology and sexually transmitted infections. > more


Contact your local sales representative for detailed information, questions and ordering.



 Browse Our Products

 Related Links